FDA's Advisory Cmte. Meeting On Bladder Pain Syndrome May Signal Policy Changes

 
• By Derrick Gingery
  
FDA entrance sign 2016
The advisory committee meeting could lead to policy changes in painful bladder syndrome.

More from US FDA Performance Tracker

More from Regulatory Trackers